Bone Marrow Transplantation最新文献_第2页

Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation. 评估接受造血细胞移植的婴幼儿的氟达拉滨标准剂量和相应暴露量。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-13 DOI: 10.1038/s41409-024-02467-0

Julia Möhlmann, Lisanne van der Ploeg, Jurgen Langenhorst, Tim Bognàr, Kim van der Elst, Marc Bierings, Alwin Huitema, Aurelia de Vries Schultink, Caroline Lindemans

引用次数: 0

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. NPM1 突变急性髓性白血病的分子可测量残留疾病监测和移植适应症。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-13 DOI: 10.1038/s41409-024-02465-2

Mary R Christopher, Mariam T Nawas, John L Reagan

{"title":"Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.","authors":"Mary R Christopher, Mariam T Nawas, John L Reagan","doi":"10.1038/s41409-024-02465-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02465-2","url":null,"abstract":"NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or intermediate-risk according to the European Leukemia Net stratification. Some patients, however, either have a poor response to initial intensive chemotherapy or ultimately relapse. NPM1 mutations are common, generally stable at early relapse and AML specific, features which make them ideal targets for measurable residual disease (MRD) monitoring. MRD monitoring via molecular analysis during the course of treatment can inform the role of allogeneic stem cell transplantation (HCT) in first remission in patients with NPM1 mutated AML with high-risk co-occurring mutations, particularly FLT3-ITD, and in favorable risk patients who do not achieve defined molecular milestones. In this review, we evaluate the prognostic role of MRD monitoring in NPM1 mutated AML and its use as a predictive biomarker to refine risk stratification and inform decision making regarding treatment. We explore the impact of pre-HCT MRD positivity on post-HCT outcomes in this AML subset, and how HCT-related factors such as conditioning intensity may influence this risk.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma. 非霍奇金淋巴瘤 CAR-T 细胞疗法失败后的应对策略。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-12 DOI: 10.1038/s41409-024-02463-4

Xiaotian Zhang, Kailin Xu, Robert Peter Gale, Bin Pan

引用次数: 0

Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. 干细胞动员能力差的多发性骨髓瘤患者第二次自体造血细胞移植后的满意疗效：代表 EBMT 慢性恶性肿瘤工作组进行的回顾性研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-12 DOI: 10.1038/s41409-024-02460-7

Matjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, Linda Koster, Frantisek Folber, Stephan Mielke, Roland Fenk, Grzegorz Basak, Jane Apperley, Jennifer Byrne, Alessandro Rambaldi, Mark Ringhoffer, Matthias Eder, Marek Trneny, Didier Blaise, Stig Lenhoff, Cecilia Isaksson, Jakob Passweg, Anu Partanen, Ioanna Sakellari, Stefan Schönland, Curly Morris, Meral Beksac, Kavita Raj, Patrick J Hayden, Donal P McLornan

{"title":"Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.","authors":"Matjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, Linda Koster, Frantisek Folber, Stephan Mielke, Roland Fenk, Grzegorz Basak, Jane Apperley, Jennifer Byrne, Alessandro Rambaldi, Mark Ringhoffer, Matthias Eder, Marek Trneny, Didier Blaise, Stig Lenhoff, Cecilia Isaksson, Jakob Passweg, Anu Partanen, Ioanna Sakellari, Stefan Schönland, Curly Morris, Meral Beksac, Kavita Raj, Patrick J Hayden, Donal P McLornan","doi":"10.1038/s41409-024-02460-7","DOIUrl":"https://doi.org/10.1038/s41409-024-02460-7","url":null,"abstract":"Autologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5-30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM). We compared the baseline characteristics and outcomes of 61 PMs and 816 non-PM patients who underwent a second auto-HCT and who were enrolled in the non-interventional CALM study (NCT01362972). Only patients who collected CD34+ prior to auto-HCT1 were included. Auto-HCT2 comprised both tandem and salvage transplants. PMs were re-mobilized with plerixafor (n = 24, 39.3%) or non-plerixafor-based regimens (n = 37, 60.7%). There were no significant differences in engraftment, progression-free survival (PFS) or overall survival (OS) after the second auto-HCT between PM and non-PM patients. There was a trend to shorter PFS in PM patients undergoing salvage auto-HCT (median 9.6 vs. 12.9 months; p = 0.08) but no significant difference in OS. The median OS was 41.1 months for PM and 41.2 months for non-PM patients (p = 0.86). These data suggest that salvage mobilization is effective and does not affect overall outcomes after a second auto-HCT.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. 异体造血细胞移植治疗多发性骨髓瘤治疗后出现的与治疗相关的骨髓性肿瘤：代表 EBMT 慢性恶性肿瘤工作组进行的回顾性研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-12 DOI: 10.1038/s41409-024-02462-5

Kavita Raj, Diderik-Jan Eikema, Sarah Lawless, Linda Koster, Desiree Kunadt, Nicolaus Kröger, Uwe Platzbecker, Matthias Stelljes, Wolfgang Bethge, Tobias Holderried, Renato Fanin, Robert Zeiser, Jürgen Kuball, Véronique Leblond, Emma Nicholson, Jakob Passweg, Victoria Potter, Jacques-Olivier Bay, Ali Bazarbachi, Lucía López Corral, Carmelo Gurnari, Christof Scheid, Joanna Drozd-Sokolowska, Treen Curly Morris, Patrick Hayden, Ibrahim Yakoub-Agha, Marie Robin, Donal P McLornan

{"title":"Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.","authors":"Kavita Raj, Diderik-Jan Eikema, Sarah Lawless, Linda Koster, Desiree Kunadt, Nicolaus Kröger, Uwe Platzbecker, Matthias Stelljes, Wolfgang Bethge, Tobias Holderried, Renato Fanin, Robert Zeiser, Jürgen Kuball, Véronique Leblond, Emma Nicholson, Jakob Passweg, Victoria Potter, Jacques-Olivier Bay, Ali Bazarbachi, Lucía López Corral, Carmelo Gurnari, Christof Scheid, Joanna Drozd-Sokolowska, Treen Curly Morris, Patrick Hayden, Ibrahim Yakoub-Agha, Marie Robin, Donal P McLornan","doi":"10.1038/s41409-024-02462-5","DOIUrl":"https://doi.org/10.1038/s41409-024-02462-5","url":null,"abstract":"Therapy-related myeloid neoplasms (t-MN) are a complication of multiple myeloma (MM) treatment. Our retrospective, EBMT registry study included 157 such patients allografted (allo-HCT) between 2006 and 2018. Most patients (130) had a prior autologous HCT. Fifty-seven (36.4%) were transplanted for t-AML and 100 (63.6%) for t-MDS. Median times from MM and t-MN diagnoses to allo-HCT were 72.6 (interquartile range (IQR), 46.1-102.9) and 6.4 (IQR, 3.9-9.4) months. Fifty-eight (38.4%) t-MN patients were in complete remission (CR) at allo-HCT predominantly conditioned with reduced intensity (70.3%). With a median follow-up of 64.9 (95% CI: 39-76) months, relapse incidence (RI) from MM at 1 and 5 years was 4% (0-10%) and 12% (2-22%), respectively, with few deaths (n = 3) only due to MM disease progression, whereas t-MN RI and non-relapse mortality (NRM) at 1 and 5 years were 35% (95% CI 28-43%) and 45% (95% CI: 36-53%) and 20% (95% CI 13-26%) and 31% (95% CI: 23-39%). Overall survival (OS) and progression-free survival (PFS) estimates at 1 and 5 years were 55% (95% CI: 47-63%) and 27% (95% CI: 19-35%) and 45% (95% CI 36-53%) and 24% (95% CI 16-32%). Older (>65 years) t-MN patients with high-risk cytogenetics do not benefit from allo-HCT.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. 更正：免疫效应细胞相关血液毒性分级自动计算方法的开发与验证。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-12 DOI: 10.1038/s41409-024-02453-6

Emily C Liang, Kai Rejeski, Teng Fei, Aya Albittar, Jennifer J Huang, Andrew J Portuguese, Qian Wu, Sandeep Raj, Marion Subklewe, Roni Shouval, Jordan Gauthier

引用次数: 0

Gender equality in wine and medicine. 葡萄酒和医学中的性别平等。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-11 DOI: 10.1038/s41409-024-02471-4

Shaun R McCann

引用次数: 0

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-08 DOI: 10.1038/s41409-024-02454-5

Lin Li, Yi Chen, Ting Chen, Yajing Xu, Panpan Zhu, Jimin Shi, Weihua Zhai, Yanmin Zhao, Yang Xu, Xiaoyu Lai, Jian Yu, Lizhen Liu, Xiaolu Song, Ting Yang, Ying Lu, Kaiqian Yang, Yimei Feng, Xiaofei Ni, Jianping Lan, Xi Qiu, Yicheng Zhang, Songfu Jiang, He Huang, Erlie Jiang, Xi Zhang, Yi Luo

{"title":"Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China.","authors":"Lin Li, Yi Chen, Ting Chen, Yajing Xu, Panpan Zhu, Jimin Shi, Weihua Zhai, Yanmin Zhao, Yang Xu, Xiaoyu Lai, Jian Yu, Lizhen Liu, Xiaolu Song, Ting Yang, Ying Lu, Kaiqian Yang, Yimei Feng, Xiaofei Ni, Jianping Lan, Xi Qiu, Yicheng Zhang, Songfu Jiang, He Huang, Erlie Jiang, Xi Zhang, Yi Luo","doi":"10.1038/s41409-024-02454-5","DOIUrl":"https://doi.org/10.1038/s41409-024-02454-5","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) utilizing mismatched unrelated donors (MMUD) present a vital option for patients with hematologic malignancies without human leukocyte antigen (HLA)-matched donors. This multicenter retrospective study encompassed 211 adults with hematological malignancies receiving allo-HSCT with antithymocyte globulin (ATG) from ≥1 HLA locus MMUD. The findings revealed cumulative incidences of II-IV acute graft-versus-host disease (GVHD) at 180 days at 26.5%, and III-IV acute GVHD at 12.3%, with 3-year cumulative incidences for total and moderate-severe chronic GVHD at 37.0% and 21.0%. The 3-year non-relapse mortality (NRM) and relapse rates were 19.7% and 25.8%. The study reported a 3-year overall survival (OS) rate of 63.1%, a disease-free survival (DFS) rate of 54.5%, and a GVHD-free, relapse-free survival (GRFS) rate of 40.8%. Administration of a lower-dose ATG-Genzyme (ATG-G, ≤ 6 mg/kg) correlated with improved engraftment without significantly affecting survival, relapse, or viral reactivation rates. The quantity of HLA mismatches did not impact engraftment, GVHD, viral reactivation, OS, DFS, GRFS, relapse, or NRM. In conclusion, MMUD allo-HSCT with ATG demonstrates favorable outcomes for patients with hematological malignancies, with no evident correlation between the degree of mismatch and post-transplantation results. Utilizing a lower dose of ATG-G ( ≤ 6 mg/kg) proved efficacious, delivering comparable clinical advantage.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis. 对于骨髓纤维化移植前的难治性脾肿大，Fedratinib 可替代脾切除术。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-08 DOI: 10.1038/s41409-024-02464-3

James T England, Taylor Nye, Verna Cheung, David R Urbach, Auro Viswabandya, Hassan Sibai, Vikas Gupta

引用次数: 0

Role of the CIBMTR biorepository and registry in precision transplantation research. CIBMTR 生物库和登记处在精准移植研究中的作用。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-08 DOI: 10.1038/s41409-024-02446-5

Ryan D Guerrettaz, Stephen R Spellman, Kristin M Page

{"title":"Role of the CIBMTR biorepository and registry in precision transplantation research.","authors":"Ryan D Guerrettaz, Stephen R Spellman, Kristin M Page","doi":"10.1038/s41409-024-02446-5","DOIUrl":"https://doi.org/10.1038/s41409-024-02446-5","url":null,"abstract":"Observational studies using registry-based data have become indispensable in our management of patients receiving hematopoietic cell transplantation (HCT) or cellular therapies (CT) for hematologic malignancies. These registries support studies that describe the natural history of disease, evaluate clinical effectiveness, or measure safety and quality of patient care. To complement registries, biobanks exist as an essential partner to provide insight on genetic, molecular, and cellular processes. In this review, we discuss and provide examples of several biobank and registry collaborations that have advanced our knowledge in the field of HCT and CT, using the Center for International Blood and Marrow Transplantation Research (CIBMTR) as a highlighted example. The CIBMTR has collected data on over 650,000 patients and has over 60,000 paired donor recipient banked samples available for research. Biospecimens and clinical data from the CIBMTR have led to advancements in our knowledge and care of conditions such as acute myeloid leukemia and myelodysplastic syndrome (MDS), as well as our understanding of the roles of HLA typing and social determinants of health. Despite the utility in advancing research, registries and biobanks do not exist without challenges which are briefly reviewed. Nevertheless, the contributions of these resources in supporting HCT/CT research are noteworthy.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0